Bristol-Myers Squibb Company

- The company plans to take on additional debt in 2024 to finance acquisitions of Karuna and RayzeBio. - Despite this new debt, the company's strong financial position and cash flow will enable it to repay approximately $10 billion of debt over the next two years to improve leverage. - There is no mention of plans for new equity fundraising in the provided excerpts. - The strategy focuses on maintaining strong operating margins and returning cash to shareholders through share repurchases and dividends. - The debt financing for acquisitions is expected to be manageable with the company's cash flow and capital allocation discipline.

- The company executed several deals toward the end of 2023 and continues to focus on integrating these acquisitions. - Business development remains a priority with ongoing interest in bolt-on acquisitions, partnerships, and licensing deals that make strategic and financial sense. - Planned acquisitions include Karuna and RayzeBio, financed through additional debt, with plans to repay approximately $10 billion of debt over the next two years. - Investments will continue in commercial execution of new product launches and growth portfolio acceleration. - Operational efficiencies and reallocation of costs within MS&A are ongoing to support investment for growth while maintaining productivity. - Additional costs related to acquisitions will result in some earnings dilution but are expected to enhance long-term growth. - Cash flow generation from ongoing operations expected to support investments and debt repayment over the medium term.

- Expect low single-digit percentage increase in reported revenues for 2024, driven by growth portfolio momentum (Page 2). - Growth portfolio sales increased approximately 15% in 2023, supporting the company’s transition strategy (Page 2). - Opdivo projected to grow modestly in 2024 with potential acceleration in 2H due to new indications (Page 2). - Eliquis expected to show strong U.S. sales growth through end of 2025 despite some generic erosion internationally (Pages 2 and 4). - Sotyktu revenue to grow via broader coverage, improved access, and increased prescriptions, targeting about 20,000 prescriptions by Q4 2024 with volume momentum into 2025 (Page 8). - Reblozyl sales expected to continue strong U.S. growth supported by label expansion and international launches, including Japan (Page 8). - Cell therapies like Breyanzi expected to show strong sales growth starting Q2 2024 driven by capacity expansion and new indications (Page 2). - Overall focus on accelerating growth in the back half of the decade, with plans for sustainable top-tier growth beyond 2028 (Page 1).

- Bristol Myers Squibb expects revenues to increase in a low single-digit range in 2024, driven by growth in the portfolio including Opdivo and recent launches. - Gross margin is projected to be approximately 74%, reflecting sales mix changes and nonrecurrence of prior hedging gains. - Operating expenses are expected to grow in the low single-digit range, accounting for Mirati costs and operational efficiencies. - Operating income and expenses (OI&E) projected at about $250 million income, including PD-1 royalty streams and Mirati-related financing costs. - The effective tax rate is anticipated around 17.5%, higher due to nonrecurrence of prior benefits and Pillar 2 impact. - Non-GAAP earnings per share guidance for 2024 is between $7.10 and $7.40. - Planned acquisitions (Karuna, RayzeBio) expected to be dilutive to EPS (~$0.30 and ~$0.13 respectively), with updates to guidance in Q1.

- For Sotyktu, net sales increased about 40% versus Q3 after normalizing for clinical trial orders, indicating growing demand and transition from Bridge to commercial orders. - Commercial paid prescriptions for Sotyktu are expected to roughly double to around 20,000 prescriptions in Q4, with volume momentum projected to continue into Q1. - There is ongoing progress in converting patients from Bridge programs to commercial use, typically taking two to three months per patient. - Access improvements with payers like ESI and Cigna have expanded coverage by approximately 40 million lives, complementing CVS's 25 million lives. Total commercial access is about 65 million lives. - Negotiations with additional payers continue to further increase access and secure improved reimbursement. - Reblozyl is experiencing strong demand with increased sales, especially after new indications and approvals in the U.S. and Japan, supporting a growing international order book. - Overall, the orderbook is strengthening through broader coverage, payer access improvements, and successful product launches.